The future of addiction therapy could soon look a lot like treatment for diabetes.
A California-based addiction treatment company hopes to change the way patients struggling with substance abuse disorder receive a popular form of medication-assisted treatment. If approved, patients could self-administer naltrexone, an opioid antagonist, in the comfort of their own homes — like insulin, but for recovering addicts.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
Why is the Globe featuring articles on its paid homepage that require an additional paid subscription? Insultingly greedy move. Whoever decided that this was a good idea, is clueless.
Because off danger of precipitating an acute withdrawal reaction giving naltrexone to an active opiate user this should only be done in a medical setting. But hey, california dope fiends get “kicks” from your grand mal seizure if you want.